Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF2α and LTB4 production; it exhibits anti-inflammatory and anti-arthritic effects in animal models without causing gastric ulcers; it demonstrates anti-proliferative activity against non-small cell lung cancer (NSCLC) cell lines, including adenocarcinoma (A549), squamous cell carcinoma (H520), and large cell lung cancer (H460); it reduces tumor volume and weight in a dose-dependent manner in vivo, with significant inhibition observed at 80 mg/kg/day.